CLINICAL RHEUMATOLOGY, cilt.41, sa.3, ss.721-730, 2022 (SCI-Expanded)
Introduction The outcomes of COVID-19 in patients with axial spondyloarthritis (ax-SpA) have not been explored in detail. Tumour necrosis factor inhibitors (TNFi) are commonly used for ax-SpA patients, and how they influence outcomes may have implications on COVID-19 management.